![Lilly Drug to Change Squamous NSCLC, but ODAC's Opinion is Nuanced](https://cdn.cancerletter.com/media/2015/07/25225454/41-27-likeunlikethumbs-up.jpg)
![Lilly Drug to Change Squamous NSCLC, but ODAC's Opinion is Nuanced](https://cdn.cancerletter.com/media/2015/07/25225454/41-27-likeunlikethumbs-up.jpg)
Cover Story
The FDA Oncologic Drugs Advisory Committee July 9 appears to have recommended approval for the Eli Lilly and Co. agent necitumumab.Yes, the word “appears” has indeed appeared in the previous sentence.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Trending Stories
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access - How a Georgetown med school student found her calling in surgery, law, and health equity
- Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health